Dr. Nayar brings an extensive 35-year career in biotechnology drug development in vaccines and liposomal drug delivery systems. Previously, he was involved in pioneering work at the Canadian Liposome Company on developing liposomal drug delivery systems in oncology. His contributions led to the development of liposomal doxorubicin (Caelyx®, Myocet®) and vincristine (Marquibo®) as marketed products addressing unmet needs in cancer treatment.
At Bayer, Dr. Nayar established the Center of Excellence for formulation and drug delivery in the biotechnology division and was responsible for managing the formulation and drug delivery activities within the global Bayer network on protein/peptide-based drugs. He was a recipient of 3 consecutive Presidential Achievement Awards at Bayer for implementing Continuous Improvement Processes in pharmaceutical development. As Founder and President of HTD Biosystems, Dr. Nayar has led the development of numerous drug products from inception to clinical trials, specializing in lyophilization, vaccine development, and innovative drug delivery systems, particularly focusing on liposomes and lipid nanoparticles (LNPs). Dr. Nayar received his Ph.D. in Biochemistry from the University of British Columbia and was a postdoctoral fellowship at the M.D. Anderson Tumor Institute as a Medical Research Council fellow where he was involved in pioneering work in immunotherapy by macrophage/monocyte activation using liposomal immunomodulators against cancer metastasis in vivo. Dr. Nayar holds 28 patents and has co-authored over 70 publications. He is notably credited with inventing Bayer's albumin-free Factor VIII formulation, Kogenate® FS, marking a significant advancement in hemophilia treatment.
Engimata is an early stage biopharma company located in the San Francisco Bay Area. Engimata has a platform nano lipid particle technology that can be used in vaccine development.
